Clinical Trial Update: Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring cadonilimab plus mFOLFIRINOX as conversion therapy in locally advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cadonilimab
• mFOLFIRINOX

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN